0001104659-20-008343.txt : 20200130 0001104659-20-008343.hdr.sgml : 20200130 20200130075934 ACCESSION NUMBER: 0001104659-20-008343 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20200130 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20200130 DATE AS OF CHANGE: 20200130 FILER: COMPANY DATA: COMPANY CONFORMED NAME: INSMED Inc CENTRAL INDEX KEY: 0001104506 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 541972729 STATE OF INCORPORATION: VA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-30739 FILM NUMBER: 20559792 BUSINESS ADDRESS: STREET 1: 700 US HIGHWAY 202/206 CITY: BRIDGEWATER STATE: NJ ZIP: 08807 BUSINESS PHONE: 908-977-9900 MAIL ADDRESS: STREET 1: 700 US HIGHWAY 202/206 CITY: BRIDGEWATER STATE: NJ ZIP: 08807 FORMER COMPANY: FORMER CONFORMED NAME: INSMED INC DATE OF NAME CHANGE: 20000128 8-K 1 tm206188d1_8k.htm FORM 8-K
0001104506 false 0001104506 2020-01-29 2020-01-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): January 30, 2020

 

 

 

INSMED INCORPORATED

(Exact Name of Registrant as Specified in Charter)

 

 

 

Virginia   000-30739   54-1972729

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification No.)

 

700 US Highway 202/206

Bridgewater, New Jersey 08807

(Address of Principal Executive Offices, and Zip Code)

 

(908) 977-9900

Registrant’s Telephone Number, Including Area Code

 

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨      Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨      Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨      Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.01 per share   INSM   Nasdaq Global Select Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

 

ITEM 5.02 – Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

Chief Financial Officer Appointment

 

On January 30, 2020, Insmed Incorporated (the “Company”) announced that Ms. Sara Bonstein has been appointed as Chief Financial Officer, to be effective January 31, 2020. Ms. Bonstein will be the Company’s principal financial officer and principal accounting officer effective upon the commencement of her employment with the Company. Prior to joining the Company, Ms. Bonstein, 39, was Chief Financial Officer & Chief Operating Officer of OncoSec Medical Incorporated, a position she held since July 2018. From February 2014 to April 2018, Ms. Bonstein served as the Chief Financial Officer, Secretary, Treasurer and Executive Vice President at Advaxis, Inc. Prior to Advaxis, Ms. Bonstein was a Six Sigma Champion & Black Belt at Eli Lilly & Company, served in various finance roles at ImClone Systems (acquired by Eli Lilly in 2008), and was a financial analyst at Johnson & Johnson in the Ortho McNeil Pharmaceuticals, Ortho Biotech and McNeil Consumer divisions.

 

Pursuant to the terms of the Company’s employment agreement with Ms. Bonstein, she will receive an initial annual base salary of $420,000 and will be eligible to participate in the Company’s benefit and compensation plans. Ms. Bonstein has been assigned an initial annual target bonus of 40% of her base salary. She will also be eligible to receive a signing bonus of $75,000 upon the completion of 30 days of employment. Ms. Bonstein will also receive an option to purchase shares of the Company’s common stock having an aggregate value of $1,500,000. The number of shares underlying the option will be determined using a Black-Scholes calculation based upon the closing price of the Company’s common stock on the Nasdaq Global Select Market on February 3, 2020. The option award agreement will be consistent with the Company’s standard stock option inducement award agreement, and the option will vest on a four-year vesting schedule, with 25% of the shares subject to the option vesting on the first anniversary of the date of grant and 12.5% of the shares subject to the option vesting every six months thereafter through the fourth anniversary of the date of grant, subject to Ms. Bonstein’s continued employment with the Company on each vesting date.

 

Ms. Bonstein’s employment agreement provides for payment of the following upon her death or disability: (i) any accrued obligations; (ii) a pro-rata portion of her annual bonus based on actual performance during the year of the termination, and (iii) any insurance benefits to which she and her beneficiaries are entitled as a result of her death or disability. If Ms. Bonstein’s employment is terminated by the Company without cause or by her for good reason (such a termination, a “qualifying termination”) within two years after a change in control, Ms. Bonstein will receive, among other things, (i) a lump sum severance payment equal to (a) one-and-a-half times her annual base salary plus (b) one-and-a-half times her target bonus plus (c) a pro-rata portion of her target bonus based on the portion of the year during which she was employed by the Company prior to the qualifying termination, (ii) full vesting of all time vested equity awards and (iii) reimbursement for up to 18 months of certain continued health and dental benefits for Ms. Bonstein and her qualified beneficiaries.

 

In the event of a qualifying termination prior to a change in control or more than two years thereafter, Ms. Bonstein would be eligible for similar benefits, although (i) her severance payment would be limited to her annual base salary and payable ratably over 12 months, (ii) her bonus would consist of any unpaid bonus for a fiscal year ending on or prior to the date of the qualifying termination and a pro-rata portion of her bonus based on actual corporate performance outcomes (75% of overall bonus) and 100% of personal performance at target (25% of overall bonus), (iii) any accelerated equity award vesting would be limited to stock options or other time-based equity awards that would otherwise have vested within 12 months following the termination date and (iv) reimbursement of certain continued health and dental benefits for Ms. Bonstein and her qualified beneficiaries would be limited to no more than 12 months.

 

 

 

There are no arrangements or understandings between Ms. Bonstein and any other person pursuant to which she was selected as an officer, and there are no family relationships between Ms. Bonstein and any of the Company’s directors or executive officers. Ms. Bonstein has no direct or indirect material interest in any existing or currently proposed transaction that would require disclosure under Item 404(a) of Regulation S-K.

 

John Goll retains the position of Chief Accounting Officer.

 

ITEM 7.01 – Regulation FD Disclosure.

 

On January 30, 2020, the Company issued a press release announcing the appointment of Ms. Bonstein as Chief Financial Officer. The press release is attached hereto as Exhibit 99.1 and incorporated in this Item 7.01 by reference.

 

ITEM 9.01 - Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit
No.		   Description
99.1   Press release issued by Insmed Incorporated on January 30, 2020.
104   The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: January 30, 2020 INSMED INCORPORATED
   
  By: /s/Christine Pellizzari
  Name: Christine Pellizzari
  Title: Chief Legal Officer

 

 

 

 EX-99.1 2 tm206188d1_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1

 

 

 

Insmed Appoints Sara Bonstein as Chief Financial Officer

 

Bridgewater, N.J., January 30, 2020 /PRNewswire/ – Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the appointment of Sara Bonstein as Chief Financial Officer, effective January 31, 2020. Ms. Bonstein will assume responsibility for leading the Company’s global financial operations, including financial planning and analysis, investor relations, accounting, tax and treasury. Sara will also serve as a member of Insmed’s Executive Committee.

 

“Sara is an exciting addition to our management team as we continue our efforts to bring ARIKAYCE® to patients around the world,” said Will Lewis, Chairman and Chief Executive Officer of Insmed. “In addition to her experience as a public company CFO, she also brings expertise in process improvement and a unique perspective from having served at both large and smaller life sciences companies. Sara is an exceptional talent and her extensive financial and leadership experience will be important as we continue to transform into a global, commercial organization, and we welcome her to the team.”

 

Ms. Bonstein joins Insmed with more than 15 years of financial and operational experience in the life sciences industry, most recently serving as Chief Financial Officer & Chief Operating Officer of OncoSec Medical Incorporated. Prior to joining OncoSec, Ms. Bonstein served as the Chief Financial Officer, Secretary, Treasurer and Executive Vice President at Advaxis, Inc. Before Advaxis, Ms. Bonstein was a Six Sigma Champion & Black Belt at Eli Lilly & Company. She also held key finance positions at ImClone Systems and Johnson & Johnson. Ms. Bonstein holds a Masters of Business Administration from Rider University and a Bachelor of Science in Finance from The College of New Jersey.

 

“I am excited to be joining Insmed in the early phase of its international commercial expansion and its ambition to bring this success to other product development opportunities aligns with my background. I look forward to leading Insmed’s financial operations and joining the executive team,” commented Ms. Bonstein. “I am confident my past experience and industry expertise will serve the Company well and further its goal to transform the lives of patients with serious and rare diseases.”

 

About Insmed

 

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product, ARIKAYCE® (amikacin liposome inhalation suspension), is the first and only therapy approved in the United States for the treatment of refractory Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a chronic, debilitating condition that can cause severe and permanent lung damage. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension. For more information, visit www.insmed.com.

 

 

 

 

Forward-looking Statements

 

This press release contains forward-looking statements that involve substantial risks and uncertainties. "Forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995, are statements that are not historical facts and involve a number of risks and uncertainties. Words herein such as "may," "will," "should," "could," "would," "expects," "plans," "anticipates," "believes," "estimates," "projects," "predicts," "intends," "potential," "continues," and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) may identify forward-looking statements.

 

The forward-looking statements in this press release are based upon the Company's current expectations and beliefs, and involve known and unknown risks, uncertainties and other factors, which may cause the Company's actual results, performance and achievements and the timing of certain events to differ materially from the results, performance, achievements or timing discussed, projected, anticipated or indicated in any forward-looking statements. Such risks, uncertainties and other factors include, among others, the following: failure to successfully commercialize or maintain U.S. approval for ARIKAYCE, the Company's only approved product; uncertainties in the degree of market acceptance of ARIKAYCE by physicians, patients, third-party payors and others in the healthcare community; the Company's inability to obtain full approval of ARIKAYCE from the FDA, including the risk that the Company will not timely and successfully complete the study to validate the PRO tool and the confirmatory post-marketing study required for full approval; inability of the Company, PARI or the Company's other third party manufacturers to comply with regulatory requirements related to ARIKAYCE or the Lamira® Nebulizer System; the Company's inability to obtain adequate reimbursement from government or third-party payors for ARIKAYCE or acceptable prices for ARIKAYCE; development of unexpected safety or efficacy concerns related to ARIKAYCE; inaccuracies in the Company's estimates of the size of the potential markets for ARIKAYCE or in data the Company has used to identify physicians; expected rates of patient uptake, duration of expected treatment, or expected patient adherence or discontinuation rates; the Company's inability to create an effective direct sales and marketing infrastructure or to partner with third parties that offer such an infrastructure for distribution of ARIKAYCE; failure to obtain regulatory approval to expand ARIKAYCE's indication to a broader patient population; failure to successfully conduct future clinical trials for ARIKAYCE and the Company's product candidates, including due to the Company's limited experience in conducting preclinical development activities and clinical trials necessary for regulatory approval and the Company's inability to enroll or retain sufficient patients to conduct and complete the trials or generate data necessary for regulatory approval; risks that the Company's clinical studies will be delayed or that serious side effects will be identified during drug development; failure to obtain, or delays in obtaining, regulatory approvals for ARIKAYCE outside the U.S. or for the Company's product candidates in the U.S., Europe, Japan or other markets, including the United Kingdom as a result of the United Kingdom’s planned exit from the European Union; failure of third parties on which the Company is dependent to manufacture sufficient quantities of ARIKAYCE or the Company's product candidates for commercial or clinical needs, to conduct the Company's clinical trials, or to comply with laws and regulations that impact the Company's business or agreements with the Company; the Company's inability to attract and retain key personnel or to effectively manage the Company's growth; the Company's inability to adapt to its highly competitive and changing environment; the Company's inability to adequately protect its intellectual property rights or prevent disclosure of its trade secrets and other proprietary information and costs associated with litigation or other proceedings related to such matters; restrictions or other obligations imposed on the Company by its agreements related to ARIKAYCE or the Company’s product candidates, including its license agreements with PARI and AstraZeneca AB, and failure of the Company to comply with its obligations under such agreements; the cost and potential reputational damage resulting from litigation to which the Company is or may become a party, including product liability claims; the Company’s limited experience operating internationally; changes in laws and regulations applicable to the Company's business, including any pricing reform, and failure to comply with such laws and regulations; inability to repay the Company's existing indebtedness and uncertainties with respect to the Company's ability to access future capital; and delays in the execution of plans to build out an additional third-party manufacturing facility and unexpected expenses associated with those plans. 

 

The Company may not actually achieve the results, plans, intentions or expectations indicated by the Company's forward-looking statements because, by their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. For additional information about the risks and uncertainties that may affect the Company's business, please see the factors discussed in Item 1A, "Risk Factors," in the Company's Annual Report on Form 10-K for the year ended December 31, 2018 and any subsequent Company filings with the Securities and Exchange Commission.

 

The Company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date of this press release. The Company disclaims any obligation, except as specifically required by law and the rules of the Securities and Exchange Commission, to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.

 

Contact:

 

Argot Partners
Laura Perry or Heather Savelle
(212) 600-1902
laura@argotpartners.com
heather@argotpartners.com

 

 

 EX-101.SCH 3 insm-20200130.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 insm-20200130_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 insm-20200130_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 tm206188d1_ex99-1img001.jpg GRAPHIC begin 644 tm206188d1_ex99-1img001.jpg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end XML 7 tm206188d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001104506 2020-01-29 2020-01-30 iso4217:USD shares iso4217:USD shares 0001104506 false 8-K 2020-01-30 INSMED INCORPORATED VA 000-30739 54-1972729 700 US Highway 202/206 Bridgewater NJ 08807 908 977-9900 false false false false Common Stock, par value $0.01 per share INSM NASDAQ false XML 8 R1.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Cover
Jan. 30, 2020
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jan. 30, 2020
Entity File Number 000-30739
Entity Registrant Name INSMED INCORPORATED
Entity Central Index Key 0001104506
Entity Tax Identification Number 54-1972729
Entity Incorporation, State or Country Code VA
Entity Address, Address Line One 700 US Highway
Entity Address, Address Line Two 202/206
Entity Address, City or Town Bridgewater
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 08807
City Area Code 908
Local Phone Number 977-9900
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.01 per share
Trading Symbol INSM
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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etaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm206188d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "tm206188d1_8k.htm" ] }, "labelLink": { "local": [ "insm-20200130_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "insm-20200130_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "insm-20200130.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "insm", "nsuri": "http://insmed.com/20200130", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm206188d1_8k.htm", "contextRef": "From2020-01-29to2020-01-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://insmed.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm206188d1_8k.htm", "contextRef": "From2020-01-29to2020-01-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r13" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The start date of the period covered in the document, in CCYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r9" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r12" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r18" ], "lang": { "en-US": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r11" ], "lang": { "en-US": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r10" ], "lang": { "en-US": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-US": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r17" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://insmed.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r11": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r12": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1-" }, "r13": { "Name": "Forms 10-K, 20-F, 40-F", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d-1" }, "r14": { "Name": "Forms 20-F, 40-F", "Number": "249", "Publisher": "SEC", "Section": "220 and 240", "Subsection": "f" }, "r15": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r18": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-13" } }, "version": "2.1" } XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} ZIP 14 0001104659-20-008343-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-20-008343-xbrl.zip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ilingSummary.xml IDEA: XBRL DOCUMENT 3.19.3.a.u2 html 1 95 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://insmed.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm206188d1_8k.htm insm-20200130.xsd insm-20200130_lab.xml insm-20200130_pre.xml tm206188d1_ex99-1.htm http://xbrl.sec.gov/dei/2019-01-31 true false